loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations

Concord Biotech Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Concord Biotech Ltd. 12 Feb 2026 12:08 PM

Q3FY26 Quarterly Result Announced for Concord Biotech Ltd.

Biotechnology company Concord Biotech announced Q3FY26 results

  • Revenue: Rs 278 crore against Rs 244 crore during Q3FY25, change 14%.
  • EBITDA: Rs 99 crore against Rs 98 crore during Q3FY25, change 1%.
  • EBITDA Margin: 35.6% for Q3FY26.
  • PBT: Rs 86 crore against Rs 101 crore during Q3FY25, change -15%.
  • PAT: Rs 64 crore against Rs 76 crore during Q3FY25, change -16%.
  • PAT Margin: 22.9% for Q3FY26.

Ankur Vaid, Joint Managing Director & Chief Executive Officer, Concord Biotech, said: Revenue for Q3FY26 grew by 14%, driven primarily by strong performance in the API segment. Following receipt of written confirmation from CDSCO, order execution has stabilized and visibility has improved. We are also witnessing positive on-ground momentum, supported by improved clarity on the US tariff environment and progress on the India–EU trade deal. We expect this to translate into higher order inflows, increased secondsource opportunities, and growing CDMO engagements.

EBITDA margins for the quarter stood at 35.6%, impacted by expenses related to the commercialization of the new injectable facility commissioned in March 2025 and the setup costs of our US subsidiary Stellon Biotech Excluding these factors, EBITDA margins would have been ~40% for Q3 & 9MFY26.

The API segment delivered robust growth of 24% during the quarter, driven by volume-led expansion and sustained market share gains. Looking ahead, we remain optimistic about the demand environment and increased product uptake, which we believe will help us sustain our historical growth trajectory.

On the strategic front, we achieved two important milestones. We received WHO-GMP certification for our injectable facility, enabling entry into the domestic Indian market through own-brand launches and contract development opportunities. In addition, we established our US subsidiary, Stellon Biotech, to drive marketing, distribution, and commercialization of Concord Biotech’s products in the US, creating a direct commercial footprint and supporting long-term global market expansion.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app